Over-the-Counter (OTC) Health Products
Incumbent-owned OTC health brands left under-innovated, exposed to cleaner-label, better-packaged, more approachable challengers.
Background
The U.S. over-the-counter drug market exceeds $36B in annual sales, with leading brands owned by incumbents like Johnson & Johnson (Kenvue), Pfizer/Haleon, Bayer, and P&G. Revenue comes from branded consumer-health product sales through retail.
The disruption thesis
OTC is under-innovated relative to supplements and beauty, partly due to FDA monograph constraints; brands offering cleaner labels, better-for-you packaging, and more approachable branding are starting to break through.
⚠Why it's ripe
- 01Slow innovation
🛡How they are defensible
No defensibility analysis yet.
⚔Emerging challengers
Startups and challengers trying to take share.
Submitted by ali@afridi.io on Jun 6, 2026
Similar companies
- LLegacy Healthcare Staffing AgenciesHealthcare · Business category
Manual, fragmented healthcare staffing agencies exposed to digital marketplaces with automated credentialing and forecasting.
- PPharmacy Benefit ManagersHealthcare · Business category
Opaque, rebate-driven pharmacy-benefit managers under regulatory pressure, exposed to transparent, pass-through, flat-fee models.
- CCVS PharmacyHealthcare · Public
Retail pharmacy with declining footfall and brutal UX
Defense3/5 - CChange HealthcareHealthcare · Subsidiary
Concentrated healthcare-claims infrastructure exposed after a major outage, ripe for resilient, AI-native rivals.
- EEpic SystemsHealthcare · Private
Hospital EHR monopoly with painful UX and high TCO
Defense4/5 - EEviCore HealthcareHealthcare · Subsidiary
Prior-authorization manager criticized for slow, manual reviews, ripe for AI-driven, transparent utilization management.